Kyverna Therapeutics appoints Nadia Dac as CCO; leads commercial launch for miv-cel in stiff person syndrome

Kyverna Therapeutics, Inc.

Nadia Dac appointed Chief Commercial Officer effective May 4, 2026; has 30+ years experience in neurology and rare disease launches.
She will lead commercial strategy for miv-cel (KYV-101), which is poised for first approval in stiff person syndrome with neuroimmunology expansion.
Previously CCO at Omeros (launched Yartemlea) and Alder (launched Vyepti); held leadership roles at AbbVie, Novartis, Biogen.
Received inducement option for 300,000 shares vesting over 4 years (25% after 1 year, monthly thereafter); exercise at May 4 closing price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.